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and induce p21WAF1 by altering chromatin of STAT
response element in A375 cells
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Background: Chrysin and its analogues, belongs to flavonoid family and possess potential anti-tumour activity.
The aim of this study is to determine the molecular mechanism by which chrysin controls cell growth and induce
apoptosis in A375 cells.
Methods: Effect of chrysin and its analogues on cell viability and cell cycle analysis was determined by MTT assay
and flowcytometry. A series of Western blots was performed to determine the effect of chrysin on important cell
cycle regulatory proteins (Cdk2, cyclin D1, p53, p21, p27). The fluorimetry and calorimetry based assays was
conducted for characterization of chrysin as HDAC inhibitor. The changes in histone tail modification such as
acetylation and methylation was studied after chrysin treatment was estimated by immuno-fluorescence and
western blot analysis. The expression of Bcl-xL, survivin and caspase-3 was estimated in chrysin treated cells. The
effect of chrysin on p21 promoter activity was studied by luciferase and ChIP assays.
Results: Chrysin cause G1 cell cycle arrest and found to inhibit HDAC-2 and HDAC-8. Chrysin treated cells have
shown increase in the levels of H3acK14, H4acK12, H4acK16 and decrease in H3me2K9 methylation. The p21
induction by chrysin treatment was found to be independent of p53 status. The chromatin remodelling at p21WAF1
promoter induces p21 activity, increased STAT-1 expression and epigenetic modifications that are responsible for
ultimate cell cycle arrest and apoptosis.
Conclusion: Chrysin shows in vitro anti-cancer activity that is correlated with induction of histone hyperacetylation
and possible recruitment of STAT-1, 3, 5 proteins at STAT (−692 to −684) region of p21 promoter. Our results also
support an unexpected action of chrysin on the chromatin organization of p21WAF1 promoter through histone
methylation and hyper-acetylation. It proposes previously unknown sequence specific chromatin modulations
in the STAT responsive elements for regulating cell cycle progression negatively via the induction of the CDK
inhibitor p21WAF1.
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Melanoma is the most aggressive skin cancer but is highly
resistant to available therapies [1]. Rapid cell proliferation
during tumorigenesis is mainly associated with two major
events, abnormalities in chromatin structure and functional
defects (mutations) in tumor suppressor genes and/or
oncogenes [2]. Recently, modifications in the chromatin
structure by the loss or gain of DNA methylation and post-
translational histone modifications have emerged as import-
ant contributors in tumor formation [3-5]. The delicate bal-
ance between histone acetyl transferases (HATs) and
histone deacetylases (HDACs) regulate the state of histone
acetylation [6]. HDACs include HDAC-1, 2, 3 and 8
belongs to Class I that are found in nucleus, HDAC-4, 5, 7
and 9 belongs to class IIa and HDAC-6 and 10 belongs to
class IIb and shuttle between nucleus and cytoplasm of the
cell [7]. A delicate balance between histone acetyl trans-
ferases (HATs) and histone deacetylases at the histone H3
and H4 tails of core nucleosomal complex affects chromatin
folding and chromosomal movement required for transcrip-
tion that leads to normal cell growth. In general histone
tails (i.e N terminal tails) are subjected to wide variety of
post-translational modifications that includes acetylation,
methylation, phosphorylation, ubiquitination, citrullination,
ADP-ribosylation and SUMOylation[2]. Such modifications
control the ability of the histone tails to interact with key
chromatin or transcriptional regulators. Among various
modifications, acetylation and deacetylation plays a central
role in controlling transcriptional activity in malignant cells
[8-10]. Histone acetylation leads to transcriptional activa-
tion where as deacetylation leads to transcriptional repres-
sion or silencing [11]. The histone acetylating enzymes
(HATs) and histone deacetylating enzymes (HDACs) can be
targeted to specific regions of the genome results in main-
tenance of acetylation based epigenetic code. This code will
be read by non-histone proteins that bind in an acetylation
dependent manner or through direct effects on chromatin
structure [10,12]. Studies on HDACs, associated with sev-
eral oncogenes and tumor suppressor genes indicate the
potential involvement of HDACs in tumorigenesis [13,14].
In addition, the pattern of histone acetylation as well as dis-
tribution of stable methylation and phosphorylation repre-
sents a functional code that is recognized by the non-
histone protein complexes involved in the regulation of
gene transcription [15-17]. However, their role in tumor
formation has not been critically analyzed.
Cell cycle progression is primarily controlled by a fam-
ily of cyclin-dependent kinases that can be negatively
regulated by CDK inhibitor p21WAF1 [14]. In many cases,
p21WAF1 activity is coupled with the histone acetylation
at the promoter level [18]. The novelty of plant chrysin
is to delocalize stable histone methylation that corrobo-
rates with other histone modifications for blocking rapid
cell proliferation in various tumor cells. More over plantflavonoids favour the localized modifications in the chro-
matin organization at the p21 promoter in tumor cells
that are distinct from other HDAC inhibitors such as
TSA, SAHA etc. Apart from p21, STAT proteins were
found to regulate the transcriptional activation of genes
that are involved in cell cycle and cell death such as Bcl-
xL, caspases, Fas, TRAIL and p21 [19]. Signal transdu-
cers and activators of transcription (STATs) are latent
cytoplasmic transcription factors that mediate various
responses such as cell proliferation, survival, apoptosis
and differentiation. STAT proteins including STAT-1, 3,
5 bind to the DNA and regulate the functions of cell
death and cell proliferation respectively [20]. Among the
different STAT proteins available in the cell only STAT-1
was found to regulate the process of cell death by tran-
scriptional mechanism involving activation of death pro-
moting genes as well as non-transcriptionally by
interacting with TRADD, p53 or HDAC [21].
Chrysin and its analogues are a group of poly phenolic
compounds that are found in fruits, vegetables, olive oil,
tea and red wine [22]. Plants produce flavonoids as second-
ary metabolites for protection against micro organisms, U.
V.light, spread of disease and gives colour to flowers. Chry-
sin is 5,7-dihydroxy flavone that was found to be cytotoxic
with EC50 value of 100 μM in wide range of cell lines such
as breast (MCF-7, MDA-MB-231 cells), colon (Lovo,
DLD-1) and prostate cancer cells [23,24]. Emerging evi-
dences have shown that Histone deacetylase inhibitors
(HDACi) such as Trichostatin A (TSA), NBM-HD-1, 3, 3'
Diindolyl methane (DIM) were found to be not only in-
hibit histone deacetylase activity but also decrease the Akt
activity that eventually lead to growth inhibition as well as
apoptosis [25-28]. Recent studies have shown the Akt in-
hibitory activity and apoptotic inducing nature of chrysin
[29,30]. But the exact molecular mechanism of action of
chrysin was not studied. In the present study we have iden-
tified that chrysin functions as HDAC-8 inhibitor and how
chrysin controls the cell cycle and cause G1 cell cycle arrest
by regulating various cell cycle proteins and histone modifi-
cations (H3acK14, H4acK12, H4acK16 and H3K9 me2) at
p21 promoter. Here we establish the role of STAT response
element (−684/−692) in the transcriptional activity of p21.
Results
Isolation, purification and characterization of novel
flavonoids
Chrysin (C15H10O4) and its two derivatives, oroxylin-A
and methoxy-chrysin (Additional file 1: Figure S1), were
extracted from the dried stem bark of the Oroxylum indi-
cum plant using petroleum ether extraction and from the
soluble fractions of the same extract using acetone (Add-
itional file 1). The identities and structures were established
by NMR (Additional file 1: Figure S2, Figure S3) and ESI-
MS analyses (Additional file 1: Table S1, Table S3). The
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results as described earlier [31]. The compounds were puri-
fied further by HPLC. The HPLC fractions that provide
greater than 97–99 % level of purity of the compounds
were considered further (Additional file 1: Figure S1).The
base structure of all three compounds is flavonoid. In orox-
ylin-A, one methoxy group (Meo) at 6th position of chrysin,
while in methoxy chrysin, the methoxy group substitution
at 7th position of chrysin (Additional file 1: Figure S1). The
presence of the voluminous hydrophobic (OH) substitute
at the R6 in the chrysin causes an inhibitory effect on DNA
cross-linking.
Role of Chrysin in cell cycle progression
The effect of the chrysin and its analogues (Figure 1A) on
the cell viability and cell cycle was determined by MTT
assay and FACS analysis in human neoplastic A375 cells.
The incubation in 40 μM chrysin or its derivatives showed
marked inhibition on cell proliferation. Chrysin having 2
hydroxyl groups cause 50 % of cell death at 40 μMFigure 1 (A) Chemical structures of Chrysin, Methoxy Chrysin and Oro
were seeded at density of 10,000 cells per well of 96 well plate and treated
(Chry) at a concentration of 40 μM and 4 μM Trichostatin A (TSA) for 24 h.
compound treatment. Data represents mean± S.D of three independent ex
(C) Comparative studies between chrysin (40 and 120 μM) and TSA (2, 4 anconcentration. At lower concentration (10 and 20 μM) a
trace level of cytotoxic effect was noticed (data not
shown). A375 cells treated with analogues of chrysin,
oroxylin A and methoxy chrysin show less cytotoxicity
(Figure 1B). But cytotoxicity was not increased proportion-
ate to the higher concentration (120 μM) in A375 cell line
over 48 h of incubation. We also compare the effect of
chrysin with known HDAC inhibitor Trichostatin A to
understand the role of chrysin on cell viability relative to
standard HDAC inhibitor TSA (Figure 1C).
In order to understand the regulatory role of chrysin
on the cell cycle progression flow cytometric analysis
(FACS) was conducted. The A375 cells treated with
40 μM of chrysin showed a strong accumulation of cells
(80 %) in the G1 phase relative to 55 % accumulation in
the DMSO treated control cells. The same cells incu-
bated at 4 μM of TSA caused 69 %G1 arrest. Chrysin
analogues such as oroxylin A and methoxy chrysin have
shown 65 % and 73 % of cells accumulated in G1 phase
(Figure 2A) when cells were incubated at 24 h. In longerxylin A. (B) Chrysin affects cell viability. Human melanoma A375 cells
with 40 μM of Oroxylin A (Oro), Methoxy Chrysin (Meo Chry), Chrysin
The cell viability of A375 cells was measured by MTT assay 24 h after
periments performed. *** represents P< 0.001; ** represents p< 0.01.
d 12 μM) was made and the cell viability was analysed.
Figure 2 Chrysin cause G1 cell cycle arrest. (A) Human melanoma A 375 cells were treated with 40 &120 μM of Chrysin (Chry), 40 μM of
Oroxylin A (Oro), Methoxy-chrysin (Meo chry) for 24 h. Cell cycle analysis was performed by flowcytometry after propidium iodide staining. The
X-axis (FL-2) shows DNA content, and Y-axis (counts) shows the number of cells presented in each phase. TSA (4 μM) was used as positive control.
(B,C &D) The data obtained from FACS analysis for a time period of 24, 48 and 72 h was represented in the form of bar diagram. Each
experiment was conducted three times and standard deviations were derived. *** indicates p< 0.001, ** indicates p< 0.01, * indicates p< 0.05.
The p-values were derived in compound treated cells when compared with control untreated cells using Graphpad software.
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in G0 (apoptotic cells) and G1 phase cells (Figure 2B–D).
Therefore, chrysin and its analogues arrest A375 melan-
oma cells at the G1 phase.
Chrysin as histone deacetylase inhibitor
It was shown earlier that HDACs 1, 2, 3 and 8 are referred
as class I type where as HDACs 4, 5, 6, 7, 9 and 10 areknown as class II type HDACs [8,32]. To characterize
chrysin as reliable and potential histone deacetylase
(HDAC) inhibitor, the effect of chrysin and a known
HDAC inhibitor Trichostatin A (TSA) on the HDAC- 8
activity was compared by in vitro HDAC enzymatic assay.
Chrysin and TSA inhibit histone deacetylase 8 (HDAC-8)
activities strongly (Figure 3A). Conversely, the reduction
in HDAC- 8 activity was relatively less in chrysin
Figure 3 Chrysin inhibits HDACs. Histone deacetylase 8 activity (A) and histone deacetylase 1/2 activity (B) was measured with compounds
Chrysin (Chry), Oroxylin A (Oro) and methoxy chrysin (Meo Chry) at 40 μM final concentration and TSA at 4 μM. The data from three
independent experiments was depicted in bar diagram. Each experiment was repeated three times. *** represents P< 0.001; ** represents
p< 0.01 (C&D) Western blot analysis of class I (HDAC-1, 2, 3, 8) and Class II (HDAC −4, 6) proteins was performed in cells treated with Chrysin
(Chry) and TSA at 40 μM and 4 μM concentrations for 24 h respectively. Chrysin was shown to decrease the HDAC-2, 3, 8 protein level.
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ing that chrysin as a potent HDAC-8 inhibitor. To further
confirm the inhibitory action of chrysin on HDAC-8 we
carried out HDAC1/2 assay. We did not observe any
change in the activity of HDAC1/2 upon addition of chrysin
(Figure 3B).
To measure the effect of chrysin and TSA on protein
levels of HDACs a series of western blot analyses was
performed using cell lysate extracted from treated A375
cells. The levels of HDAC-2, 3 and 8 proteins were sig-
nificantly decreased by treatment of chrysin (40 μM) or
TSA (4 μM) (Figure 3C). However their effect is less
pronounced in HDAC-1 protein. In contrast , cells trea-
ted with chrysin and TSA did not show significant effect
on HDAC-4 and 6 protein levels relative to control (C)
untreated cells (Figure 3C & 3D). Therefore chrysin
functions as HDAC-2 & 8 inhibitor. Similarly apigenin, aflavonoid and a close analog of chrysin was found to
inhibt the histone deacetyalse activity [33].
Regulation of cell cycle components
Previous studies have established that deacetylation of his-
tones by HDAC enzymes cause inactivation of tumor sup-
pressor genes leading to neoplastic transformation [34]
Inhibition of HDAC enzymatic activity restores the expres-
sion of many tumor suppressor genes. Thus the amount of
tumor suppressor proteins p53, p27 and p21WAF1 was esti-
mated from the cell lysates of A375 neoplastic cells incu-
bated with 0.1 % DMSO, chrysin and TSA containing
media. The p21WAF1 protein in A375 cells was increased 4-
folds in 40 μM chrysin, while there was no significant
change in the level of p27 protein. The expression of tumor
suppressor protein p53 was drastically reduced in chrysin
treated cells when compared to control untreated cells
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hibitor has shown similar effect on mRNA and protein
levels of p21 and p53 [1]. Apigenin, a flavonoid caused p21
induction with the increase of p53 in 22Rv1 cells and the
same compound caused p21 induction in PC-3 prostate
cancer cells which lacks p53. Thus p21 induction is cell
type dependent and is independent of p53 status [33].
P21 is a cdk inhibitor whose activation leads to cell
cycle arrest or apoptosis [35]. Although the role of p21
in apoptosis is controversial, the HDAC inhibitor sodium
butyrate has induced apoptosis in MCF-7 breast cancer
cells. Thus acts as a modulator of apoptosis [36]. As cyc-
lin-dependent kinases (Cdks) and cyclins are required for
the complex formation with p21WAF1, the level of Cdk2,
Cdk4 and Cyclin D1, that regulate G1-S phase transition
was also estimated in chrysin (40 μM) and TSA (4 μM)
treated cells (Figure 4A). Reduction in cyclin D1 and
cdk2 protein level with no change in cdk4 was noticed.
To confirm the importance or dependency of p21 induc-
tion on p53 and STAT-1 status A375 cells were treated
with chrysin (40 μM) and TSA (40 μM) in K562 (p53 null)
[37] and U3A ( STAT-1 null) cells for 24 h and conducted
western and RT-PCR analysis. We observed pronounced
increase (3–4 folds) of both mRNA and protein level of
p21 in case of K562 cells and drastic reduction in case of
U3A cells. This shows the functional dependency of p21
on STAT-1 protein than p53 protein. Similar results of
STAT-1 dependency, p53-independent expression of p21
modulating apoptosis was observed in oxysterol com-
pound treated cells [38] (Figure 4B, 4C & 4D).
To further confirm whether p21WAF1 induction occurs at
the transcriptional and post-transcriptional level, nuclei
were prepared from the cells incubated in 40 μM chrysin
or 0.1 % DMSO containing culture media. The results of
the nuclear run-on experiments showed that the amount of
nascent p21WAF1 transcripts was increased more than 2.5-
fold (Figure 4D). To further confirm the expression of p21
mRNA in chrysin treated A375 cells quantitative real-time
PCR analysis was conducted and there was upto 4-fold in-
crease in the p21 mRNA level in chrysin treated cells
(Figure 4E).
Dual post-translational histone tail modifications
HDACs are the major proteins that control the nucleo-
some conformation and chromatin organization. To
identify causal factors for induction of p21WAF1, distinct
chromatin modifications such as, acetylated histone H3
and H4 proteins were assayed from the A375 cells that
are incubated in different compounds (0.1 % DMSO,
40 μM chrysin and 4 μM TSA) for 24 h. Western blot
analyses was carried out by probing with acetylated his-
tone [ H3 Lysine 14, H4 Lysine 12 ,H4 Lysine 16] and
histone H3 and H4 antibodies. Culture of the A375 cells
in chrysin and TSA containing media induced acetylatedhistone (i.e H3acK14, H4acK12, H4acK16) levels markedly
(Figure 5A, 5B). Therefore typical to HDAC inhibitors,
chrysin improves acelylated lysine levels of histone H3 and
H4 tails in A375 tumor cells. Incubation in chrysin (40 μM)
and TSA (4 μM) reduces methylation signals (H3me2K9)
by 3-folds. These findings demonstrate that chrysin-
dependent modulation of acetylation and methylation of
histone (H3 and H4) lysine residues form a functional com-
plex that might add the epigenetic marks on the chromatin
structure required for blocking rapid cell proliferation
(Figure 5A, 5B).
Histone tail modification in inter-phase nuclei and
distribution of histone modifiers in the metaphase
chromosomes
To visualize the accumulation of histone acetylation in the
interphase nuclei, A375 cells were treated either with 0.1 %
DMSO, chrysin (40 μM), TSA (4 μM) separately for 24 h
and processed for indirect immuno-fluorescence using his-
tone H3acK14 and H4acK12 antibodies. Increase in the
acetylation of histone H3acK14 and H4acK12 in the A375
cell nuclei was observed (Figure 5C–5E). The increased
acetylated H3K14 and H4K12 by chrysin was strongly cor-
related with the cell cycle arrest and p21WAF1 induction.
Similar results were also observed in metaphase spreads
with respect to acetylation pattern of histones H3 and H4
(i.e H3ack14 & H4ack12) (Figure 5F, 5G).
Further we have focussed on pattern of histone methyla-
tion in chrysin and TSA treated cells. Incubation with chry-
sin (40 μM) and TSA (4 μM) showed a clear reduction in
the number of histone H3me2K9 foci (Figure 6A). A statis-
tical profile demonstrated that chrysin increased histone H3
and H4 acetylation uniformly in the interphase nuclei of the
cancer A375 cells, but decreases lysine9 methylated H3 pro-
teins in the same nuclei (Figure 6B). Our analysis also
showed that the distribution of H3me2K9 foci on the meta-
phase chromosomes isolated from DMSO treated A375
cells (control cells) was more intense than the chrysin
exposed cells (Figure 6C). However, no apparent changes in
the distribution of foci at the chromocentre were noticed
when cells were exposed to chrysin and control DMSO.
Therefore, the loss of histone H3me2K9 is mostly limited to
the euchromatic domains. Conversely, a greater accumula-
tion of acetylated histone signals reveals that chrysin might
be required for chromatin organization changes for arrest-
ing the rapid cell growth. Thus differential distribution of
acetylated and methylated lysines by chrysin on the different
chromosomal locations marked functional distinction of
chromatin organization.
Accumulation of acetylated histone and displacement
from p21WAF1 promoter
To correlate p21WAF1 induction and localized chromatin
organization, the binding of acetylated and methylated
Figure 4 Effect of chrysin on proteins that regulate cell cycle. (A) The effect of chrysin on Cdk4, Cdk2, Cyclin D1, p53, p21 and p27 proteins
were determined by Western blot analysis from the total protein extracted from A375 cells after incubating with 40 μM of Chrysin and 4 μM of
TSA for a time period of 24 h. The blots were reprobed with Tubulin antibody that acts as gel loading control. C is the control untreated cells.
C +D: is the control cells treated with DMSO (0.1 %). Bar diagram representing the intensity of expression of p21, p53, p27, cyclin D1, Cdk2
proteins. (B) The induction of p21 protein by compounds Chrysin 40 μM(Chry) and TSA 4 μM was studied by western blot analysis in K562
leukemia cells which is null for p53 and U3A, fibrosarcoma cells which is null for STAT-1 . We observed induction of p21 was independent of p53
and dependent on STAT-1. C: Control, untreated cells and C+D represents control untreated cells incubated with 0.1 % DMSO. Each experiment
was conducted three times and standard deviations were derived. Data represents mean± S.D of three independent experiments performed.
*** represents P< 0.001; ** represents p< 0.01. (C) The effect of chrysin on mRNAlevels of p21 in K562 (p53−/−) and U3A (STAT1 −/−) cells. P21
induction was observed 3–4 folds in chrysin (40 μM) treated K562 cells but not in U3A cells which lack STAT-1 . These treatments were carried out
for 24 h (D) Transcriptional run-on assays using radio-labeled nuclear RNA extracted from 0.1 % DMSO and chrysin (40 μM) treated A375 cells
after 24 hrs. Actin nuclear RNA was used as internal control. The relative ratio of P21/ Actin from triplicate blots were shown in a bar chart.
*** represents P< 0.001; ** represents p< 0.01. (E) The quantitative real-time PCR assay for the p21 mRNA in chrysin (40 μM) and TSA (4 μM)
treated A375 cells for 24 h. Control indicates cells treated with DMSO (0.1 %).
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Figure 5 Effect of chrysin on histone acetylation and methylation. (A) Histone protein expression pattern with respect to acetylation and
methylation in the chrysin (40 μM) treated cells The amount of histone H3acK14, H4acK12, H4acK16 and histone H3 dimethyl lysine 9 are
measured by Western blot analysis from A375 cells treated with DMSO, chrysin (40 μM) and TSA (4 μM) for 24 h. The blots are re-probed with
total histone H3 and histone H4 proteins for gel loading control. (B) Bar diagrams representing the relative ratio (mean ratios ± S.D) between
histone modifications upon chrysin and TSA treatment and were calculated from three independent experiments. *** represents P< 0.001;
** represents p< 0.01. (C&D) Human melanoma A 375 cells were treated with chrysin at 40 μM concentration and TSA at 4 μM concentration
and the nuclei were subjected to immunostaining using H3acK14, H4acK12 antibodies. (E) Quantitative estimation of histone modifications
(H3acK14 and H4acK12) in interphase nuclei in TSA and chrysin treated cells. Histogram represents quantitative measurement of histone H3acK14
and H4acK12 status as fluorescence intensity. (F&G) Metaphase spreads isolated from pre-incubated A375 cells with chrysin 40 μM and control
untreated cells hybridized with histone H3acK14 and H4acK12 antibodies. Corresponding DAPI stained images of the same metaphase spreads are
shown. Scale-10 μm.
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Figure 6 Chrysin delocalizes methylated histone lysine 9 foci in the interphase nuclei and metaphase chromosomes in A375 cells.
Nuclei and chromosomes were prepared from A375 cells cultured in 0.1 % DMSO, 40 μM chrysin, and TSA (4 μM) for 24 h. (A) Interphase nuclei
were immunostained with H3me2K9 foci in counterstained with DAPI. Merge figures are shown in the panel. Scale-10 μm (B) Bar diagram shows
amount of histone H3me2K9 antibody hybridized with interphase nuclei based on fluorescence intensity. Number of nuclei (n) in each cell is
noted below. *** represents P< 0.001. (C) Metaphase chromosomes immunostained with H3me2K9 antibody. The chromosomes were prepared
from DMSO treated and 40 μM chrysin A375 cells for 24 hrs.
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using ChIP assay. Since induction of p21WAF1 expression
occured independent of p53 and other members of the Cdk
family, we had selected four distinct regions of the p21WAF1
promoter including two STAT binding sites (Figure 7A)
[39]. Chromatin immuno precipitation assay (ChIP) was
conducted to know the effect of chrysin (40 μM) on p21
promoter with regard to STAT1 and histone proteins is
concerned. The DNA from the immunoprecipitated chro-
matin of the A375 cells after incubating in chrysin (40 μM)
for 24 hrs was amplified by the quantitative Real-time PCR.
The amplified proximal region (−194 to −84) by primer 4
carries core promoter region including the TATA box, the
SP1/SP3 binding sites, the E boxes and Ap2 sites [39].
No change in the histone modification was observed
(Figure 7B). The second selected region (−421 to −137)
amplified by the primer pair 3, which does not contain any
typical binding sites represent a non-specific region of
p21WAF1 promoter. The histone proteins are almost
uniformly distributed with no trace of STAT-1 protein.
However, two different amplified fragments (−742 to −488
and −2894 to −1753) carrying STAT protein binding site
(TTCNNNGAA) showed a marked enrichment of theacetylated histones H3 and H4 (i.e H3acK14, H4acK12). On
the contrary, H3 Lysine 9 methylation on the same regula-
tory region was reduced in the chrysin treated cells relative
to the control untreated cells (untr). The acetylated histones
H3ack14, H4ack12 was increased to 3–4 folds in chrysin
treated cells. While histone H3k9 methylation showed a
profound reduction upto 3-folds in chrysin treated cells in
region −742 to −488. Whereas 3-fold increase in H3ack14,
2.5-folds increase in H3ack12 and 2.5-fold decrease in
H3k9 methylation in −2894 to −1753 region was observed.
The STAT-1 protein levels were increased in both the
regions (ie. −742 to −488, −2894 to −1753) (Figure 7B).
Therefore histone tail modifications at the STAT response
element are required for p21WAF1 induction and might
serve as a switch for p21WAF1 induction by controlling his-
tone modifications [39]. To further confirm the greater
accumulation of STAT-1 protein occurred by chrysin expos-
ure, p21 protein was immunoprecipitated and is followed
by western blot analyses using STAT-1, 3 and 5 antibodies.
Both STAT-1, 3 proteins were increased at an equal level
after TSA and chrysin treatment where as STAT-5a was
found to be decreased. Probably the ratio of STAT1 and 3
might regulate the cell death event (Figure 7C, 7D). We
Figure 7 Effect of chrysin on histone modifications and STAT-1 at p21 promoter. (A) Schematic diagram of the human p21WAF1 promoter
illustrating regulatory factor binding sites like −119 (BRCA1), -692 (STAT-1/3/5), -1203 ( RAR), -1394 and −2285 (P53RE), -4232 and −2557 are the
(STAT1/3/5) binding sites.The arrow indicates transcriptional start site at +1. (B) Four different regions (−194/-84, -421/-137, -742/-488, -2894/-1753)
were amplified by quantitative real time PCR after chromatin immunoprecipitation to observe the region that is highly sensitive to the treatment
with chrysin in A375 cells using anti-H3acK14, H4acK12, H3me2K9 and STAT1 antibodies. untr: untreated cells, tr: treated cells.Table below the
diagram shows relative location of the four primer pairs used in ChIP assay. (C) Effect of chrysin on the expression of p21 associated STAT proteins
in Chrysin and TSA treated A375 cells (i.e STAT-1, STAT-3 and STAT-5a). (D) Graphical representation of STAT protein expression that is associated
with p21 in chrysin (40 μM) and TSA (4 μM) treated cells for 24 h time period. *** represents P< 0.001. (E) A375 cells were treated with Chrysin
(40 μM) and TSA (4 μM) for 24 h and mRNA was isolated and checked for STAT-1 expression. *** indicates p< 0.001, ** indicates P< 0.01.
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change in the STAT-1 mRNA level in chrysin (40 μM) trea-
ted cells. We found an increase in STAT-1 mRNA level in
chrysin treated cells (Figure 7E).
The acetylated histone pattern was increased 2.5 to
3-folds by the incubation in chrysin and TSA containing
media, while histone H3K9 methylation showed a pro-
found reduction (4–6 folds) in 40 μM chrysin and 4 μM
TSA treated cells. Conversely no changes in the histone
acetylation and methylation levels were detected in the
p27 promoter by the chrysin incubation (data not
shown).
STAT response element (−692/-684) is important for
chrysin mediated p21WAF1 promoter activity
ChIP analyses reveal that STAT binding site of the
p21WAF1 promoter is critical for p21 induction by chrysin
(Figure 8A). Thus A375 cells were transfected with 1 μg
of p21 promoter (p21-luc) and 500 ng of CMV-β-galac-
tosidase followed by incubation in 0.1 % DMSO, 40 μM
chrysin and 4 μM TSA for 24 h and assayed the lucifer-
ase activity. β-galactosidase values obtained were used
for normalization of luciferase activity. Here DMSO trea-
ted cells was used as control. TSA incubated cells have
shown 3-folds of p21WAF1 promoter activity whereas
chrysin treatment caused a marked increase (6-folds) inFigure 8 Effect of chrysin on p21WAF1 promoter acivity and role STAT
promoter with essential motifs such as 6 Sp1 sites (from −1 to −119), STAT
-2281/-2262. (B) Representation of wild-type STAT response element (5’-TTC
(C) Graph representing p21 promoter activity in A375 cells transfected with
and TSA (4 μM) for 24 h. Chrysin treated cells showed 5–6 fold increase in
promoter activity as observed by normalized luciferase values. β-galactosidapromoter activity (Figure 8B, 8C). But the activity was
reached to basal level in cells transfected with STAT
mutated p21 construct followed by chrysin (40 μM) and
TSA (4 μM) treatment.
The mutation of the STAT site fail to activate the chry-
sin induced p21WAF1 activity, which suggests STAT re-
sponse element at −692 to −684 is critical for chrysin
mediated transactivation of p21WAF1 promoter. It indi-
cates that chrysin is capable of activating p21 transcrip-
tion through the promoter element in the region −742 to
−488 bp containing STAT1/3/5 binding site.
Effect of chrysin on apoptosis
STAT-1 and p21 are essential proteins that are involved
in modulation and regulation of apoptotic process
[36,38]. Recent studies have also focussed on HDAC
inhibitors and their repressive role on NF-kB dependent
genes i.e Bcl-xL, Survivin [40] to control cell prolifera-
tion. Thus we have treated A375 cells with chrysin
(40 μM) and TSA (4 μM) for 72 h and lysates were sub-
jected to western blot analyses. We observed a drastic
decrease in the levels of anti-apoptotic proteins such as
Bcl-xL (a Bcl-2 family protein) and survivin. Interestingly
an increase in the level of effector caspase (caspase-3)
was also observed. Thus chrysin has a potential role in
causing apoptosis (Figure 9).response element in A375 cells. (A) The representation of p21
binding site (−692/-684), p53 response element (p53 RE) -1376/-1395,
CCGAA-3’) and mutant STAT response element (5’-ATGCGGTA-3’).
p21 promoter which is followed by treatment with chrysin (40 μM)
promoter activity. TSA treated cells showed only 3-folds increase in
se O.D values were used for normalizing the Luciferase values.
Figure 9 Chrysin induce apoptosis in A375 cells. Human melanoma cells. (A375 cells) were treated with TSA (4 μM) and Chrysin (40 μM) for
72 h. The cell lysates were subjected to Westernblot analysis with antibodies against Bcl-xL, survivin and active caspase-3. Each experiment was
conducted three times. *** indicates p< 0.001, ** indicates p< 0.01 * indicates p< 0.05. P values were generated in compound [Chrysin (40 μM),
TSA (4 μM) ] treated cells when compared to control cells using graph pad soft ware.
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Cancer is caused by abnormal cell cycle progression.
Mammalian cell cycle progression involves the activities
of cyclins and cdks. The balance between the activation
and inhibition of cyclin/ Cdk inhibitor proteins decide
whether cell will proceed through cell cycle or cause
cancer [41,42]. Chrysin caused 50 % cytotoxicity than
other analogs and this result is in corroboration with the
fact that only two hydroxyl groups in AC rings of flavon-
oid were responsible for effective cytotoxicity. Increase
or decrease of -OH groups in flavonoids would lead to
loss of potent cytotoxicity [23]. Flowcytometric analysis
with chrysin treatment caused an increase in G1 phase
cells with concomitant decrease in the number of S and
G2/M phase cells, thus confirming G1 cell cycle arrest
nature of the compound (Figure 2). Increased time dur-
ation of incubation lead to increase of G0 and G1 phase
cells. Similar to chrysin, the other HDAC inhibtors such
as SAHA and NaB (sodium butyarte) cause G1 cell cycle
arrest in neuronal stem cells [43].
Recent developments revealed that HDAC inhibitors
are gaining interest as potential anti-cancer drugs due to
their ability to reactivate epigenetically silenced genes in
cancerous cells and there by control growth arrest, apop-
tosis and differentiation [44]. The HDAC activity within
the cells can be altered by direct inhibition of HDAC
enzyme as well as changes in HDAC protein expression.
We found decrease in the level of HDAC-8 protein as
well as enzyme activity in the chrysin treated melanoma
cells (neoplastic) (Figure 3). Similarly decrease in activity
and protein levels of HDACs was observed in the case of
recent studies on HDAC inhibitors such as Allyl mercap-
tan (AM), NBM-HD-1, apigenin [26,33,45]. It is a well
established concept that HDAC inhibitors induce apop-
totic response in a P53-dependent and independent ways
[46]. In our study we have observed induction of p21
protein and mRNA in A375 cells with drastic reduction
in the p53 protein, level indicating chrysin mediated p21
induction is independent of p53 status in A375 melan-
oma cells. The p53 independent induction of p21 activitywas observed in studies on TSA and Apigenin, a well
known flavonoid. This mechanism was reported to be
cell type dependent (Figure 4) [1,33].
Typical to HDAC inhibitor, chrysin and its analogues
can arrest cell growth and induce p21WAF1 transcription
[47-49], but its mechanism of action is quite different
from known HDAC inhibitors (TSA). It selectively
enhances the accumulation of acetylated histones and
STAT proteins at the STAT binding site of the p21WAF1
promoter (Figure 5). Indeed, the novelty of the plant
chrysin is to delocalize methyl group from the histone H3
lysine 9 from the STAT response element (−692 to −684)
(Figure 6). Reduced histone methylation by treatment
with chrysin acts sequentially or in concert with the ele-
vated histone acetylation that might form a complex “his-
tone code”. Such fine-tuning in the chromatin structure
precisely in STAT responsive sequence might recognize
the non-histone proteins for the transcriptional activation
of cdk-inhibitor p21WAF1 gene [15,16,50].
Further, the modulations of histone methylation and
acetylation by chrysin might initiate several levels of
chromatin modification in the multiple sites such as
−684 to −692, −2549 to −2557 required for transcrip-
tional regulation of p21 gene [51]. The histone methyla-
tion functions to regulate the chromatin organization
directly by affecting higher order packaging of chromatin
fiber and is required for the gene transcription and DNA
repair mechanism by changing the accessibility of DNA
to several transcriptional factors [52,53]. It is known that
histone lysine methylation of H3k4 is associated with
promoters of actively transcribed genes [54] where as
H3K9 lysine methylation is associated with heterochroma-
tin formation [55]. Jumonji-C (jmjC) domain containing
enzymes constitute the largest class of histone demthylases
which includes JMJD2c and LSD1 and is linked particularly
in prostate cancer [56]. Thus we propose that histone tail
modifications by the plant chrysin such as methylation and
acetylation of lysine are the prominent epigenetic marks
that regulate the binding of different transcriptional factors
[57-59]. Consistent with this notion, histone modification
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STAT binding sites in the p21WAF1 promoter [60,61].
The mode of action of chrysin is distinct from the
known HDAC inhibitors such as SAHA and TSA. Treat-
ment of SAHA and TSA inhibits LSD1, the known his-
tone lysine demethylase I which demethylate both mono
as well as dimethyl lysine 4 of histone H3 that lead to
the chromatin modification at the p21WAF1 promoter
[62]. But function of chrysin is unique and novel from
known HDAC inhibitors which decrease the H3k9
dimethylation at the p21WAF1 promoter.
Emerging evidence has indicated p53 independent tran-
scriptional activation of p21 include STAT1, MyoD1 and
BRCA1 [63]. Precisely, this study also shows a new regula-
tory relationship between p21WAF1 and STAT proteins via
epigenetic modulation [64]. The changes in the histone
code of the chromatin in or near STAT binding sites by
the chrysin can increase accessibility of the STAT-1& 3
proteins that lead to activate STAT mediated induction of
p21WAF1 expression (Figure 7). Earlier studies indicated the
involvement of STAT-1 dependent and p53-independent
expression of p21 controlling apoptosis [38]. These results
not only suggest that chromatin remodeling within the
STAT responsive sites can control transcriptional regula-
tion but also demonstrate that modification in core histone
tails by chrysin might activate STAT signals in A375 cells.
STAT activated signals in response to IFN-gamma are dir-
ectly involved in regulating p21WAF1 expression [65].
Nevertheless our findings led to propose a chrysin based
novel epigenetic pathway of p21WAF1 regulation by which
an increased recruitment of STAT-1and-3 to proximal
responsive region from the transcriptional start site in the
p21 promoter that maintain a pivotal role in the p21WAF1
up regulation. We speculate that some unknown binding
factors may form a complex with STAT1/3/5 proteins
in vivo in the presence of chrysin to facilitate STAT1, 3 & 5
for easy recognition and accessibility to the two STAT
binding sites. It could be very interesting to identify such
chrysin-regulated proteins that bind to STAT binding sites.
In fact, our studies indicate that modification of chro-
matin structure in response to histone acetylation and
methylation of the two responsive sites is sufficient to
allow the transcriptional activation of p21WAF1 presum-
ably via STAT proteins (Figure 8). These findings dem-
onstrate a possible working model of chrysin for not
only regulating cell cycle but also connect epigenetic
modulation of p21WAF1 promoter and STAT signaling
pathway as well. The functional importance of STAT
region in the promoter activation was highly elucidated.
In this study we found that chrysin treatment caused
decrease in the protein level of NF-kB dependent genes
such as Bcl-xL, survivin that lead to cell death (apop-
tosis) by enhancing the activity of caspase-3.Thus chrysin
can be used as a single drug when compared withcombinatorial therapy such as recently used HDAC
inhibitor and demethylating agent (Aza Cytidine).
Conclusions
In summary, we have shown that chrysin posses potent
invitro anti-cancer activity by suppressing cell prolifera-
tion, inducing G1 cell cycle arrest with the upregulation
of p21 and decrease in cyclin D1, cdk2 protein levels.
This compound caused inhibition of HDAC-8 activity
with no effect on the activity of HDAC-1/2. The protein
levels of HDAC- 2, 3 and 8 (Class I HDACs) were
found to be drastically reduced with no change in
HDAC- 4 & 6 (class II HDACs) upon chrysin treat-
ment. Chrysin caused histone modifications such as
acetylation and methylation at p21 promoter particu-
larly at STAT binding site (−692/−684) and resulted in
increased p21 promoter activity. More over chrysin as a
HDAC inhibitor cause apoptosis by decreasing the
levels of NF-kB targeted and HDACi related genes such
as Bcl-xL , survivin and increased the level of caspase-3
proteins.
Methods
Chemical structure and extraction of natural compounds
The dried stem bark of dundilum tree, Oroxylum indicum
was grinded and extracted consecutively with hexane in a
soxhlet apparatus. Solid residue (2.5 g) in the hexane
extract was filtered and subjected to silica gel (60–120
mesh) column chromatography to isolate two major frac-
tions (F1 & F2). Fraction F1 was purified on silica gel
column chromatography (60–120) eluted with 0.5 % MeoH
in Chloroform to isolate methoxy chrysin (0.25 g). Simi-
larly, Fraction F2 was subjected to repeated column chro-
matography with the elution of 2 % MeoH in Chloroform
to isolate oroxylin A (1.2 g) and chrysin (0.8 g). The purifi-
cation, chemical structure and characterization of all three
compounds were determined via extensive spectroscopic
NMR, ESI-MS, and HPLC methods. The conserved methyl
oxide and hydroxyl group are shown in the chemical struc-
ture of small flavonoid compounds.
Cell culture
A375 ( human melanoma), U3A (Fibrosarcoma) cell lines
were maintained in DMEM ( Dulbecco’s Modified Eagle’s
Medium). Whereas K562 ( human Leukemia) cell line
was maintained in RPMI media. All three cell lines were
supplemented with 10 % FCS, 1 % pencillin/ streptomycin
& 5 % glutamine. These cell lines were grown at 370 C in
a humidified chamber containing 5 % CO2.
MTT assay
Cell viability was assessed by the MTT assay, a mitochon-
drial function assay. It is based on the ability of viable cells
to reduce the MTT to insoluble formazan crystals by
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96-well plate at a density 10,000 cells/well. After overnight
incubation, cells were treated with compounds chrysin,
methoxy chrysin, oroxylin A at a final concentration of
40 μM and Trichostatin A (TSA) at a final concentration of
4 μM and incubated for 24 h. Medium was then discarded
and replaced with 10 μL MTT dye. Plates were incubated
at 37°C for 2 h. The resulting formazan crystals were solu-
bilized in 100 μL extraction buffer. The optical density
(O.D) was read at 570 using micro plate reader (Multimode
Varioskan Flash Instrument-Themo Scientific Ltd).
Cell Cycle Analysis
5 X 105 A375 cells were seeded in 60 mm dish and were
allowed to grow for 24 h. Compounds chrysin, oroxylin
A, methoxy chrysin at 40 μM final concentration as well
as TSA (positive control) at 4 μM final concentration
were added to the culture media, and the cells were
incubated for an additional 24, 48 and 72 h. Cells were
harvested with Trypsin-EDTA, fixed with ice-cold 70 %
ethanol at 4°C for 30 min, washed with PBS and incu-
bated with 1 mg/ml RNase A solution (Sigma) at 37°C
for 30 min. Cells were collected by centrifugation at
2000 rpm for 5 min and further stained with 250 μL of
DNA staining solution [10 mg of Propidium Iodide (PI),
0.1 mg of trisodium citrate, and 0.03 mL of Triton X-100
were dissolved in 100 mL of sterile MilliQ water at room
temperature for 30 min in the dark]. The DNA contents
of 20,000 events were measured by flow cytometer
(DAKO CYTOMATION, Beckman Coulter, Brea, CA).
Histograms were analyzed using Summit Software.
Protein extraction and Western blot analysis
5 X 105 A375 cells were seeded in 60 mm dish and were
allowed to grow for 24 h. 40 μM concentration of chrysin
and 4 μM concentration of TSA were added to the culture
media, and the cells were incubated for an additional 24 h.
Total cell lysates from cultured A375 cells were obtained
by lysing the cells in ice-cold RIPA buffer (1X PBS, 1 %
NP-40, 0.5 % sodium deoxycholate and 0.1 % SDS) and
containing 100 μg/mL PMSF, 5 μg/mL Aprotinin, 5 μg/mL
leupeptin, 5 μg/mL pepstatin and 100 μg/mL NaF. After
centrifugation at 12,000 rpm for 10 min, the protein in
supernatant was quantified by Bradford method (BIO-
RAD) using Multimode varioskan instrument (Thermo-
Fischer Scientifics). Fifty micrograms of protein per lane
was applied in 12 % SDS-polyacrylamide gel. After electro-
phoresis, the protein was transferred to polyvinylidine
difluoride (PVDF) membrane (Amersham Biosciences).
The membrane was blocked at room temperature for 2 h
in 1X TBS+0.1 % Tween20 (TBST) containing 5 % block-
ing powder (Santacruz). The membrane was washed with
TBST for 5 min, and primary antibody was added and
incubated at 4°C overnight. P53, p21, p27, cyclin D1, cdk2,cdk4, Bcl-xL and STAT-1, 3, 5a antibodies were purchased
from Santacruz and Millipore companies. Survivin, active
caspase-3 and β-actin were purchased from Imgenex com-
pany. Membranes were washed with TBST three times for
15 min and the blots were visualized with chemilumines-
cence reagent (Thermo Fischer Scientifics Ltd.). The X-ray
films were developed with developer and fixed with fixer so-
lution purchased from Kodak Company.
HDAC- 8 assay
The HDAC-8 fluorimetric drug discovery kit is based on
the unique fluoro de lys HDAC-8 substrate and devel-
oper combination. Here the compound was incubated
with the fluoro de lys substrate and HDAC-8 (BML-SE
145) for 30 min to observe the inhibitory activity of plant
flavonoids (Oroxylin, methoxy-chrysin, chrysin) at a final
concentration of 40 μM and known HDAC inhibitor
TSA at 4 μM on the HDAC-8 protein. The deacetylation
of substrate sensitizes the substrate and developer will
produce fluorophore (Enzo Life Sciences USA). The
fluorescent readings recorded using Multimode varios-
kan instrument (Thermo scientific, USA).
HDAC-1/2 assay
The HDAC-1 and 2 calorimetric assay drug discovery kit is
based on the unique Color de lys substrate and developer
combination. Here the compound was incubated with the
de Color lys substrate and HDAC-1 and 2 (BML-K 1137)
for 30 minutes to observe the inhibitory activity of plant
flavonoids ( Oroxylin, methoxy-chrysin, chrysin ) at 40 μM
and known HDAC inhibitor TSA at 4 μM on the HDAC-1
and 2 proteins. The deacetylation of substrate sensitizes the
substrate and developer will produce yellow colour that
can be measured by absorption of 405 nm (Enzo Life
Sciences USA). The calorimetric readings recorded using
Multimode varioskan instrument (Thermo scientific, USA).
Histone isolation and Western Blotting
The A375 were initially incubated with DMSO, TSA
(4 μM) and Chrysin (40 μM) separately in 100 mm
dishes with noted concentration for the stipulated time
and followed by the washes with cold PBS (2–3 times).
The cell lysate was passed through 26 G syringe 10
times and centrifuged at 12,000 g for 20 sec. The pellet
was washed briefly with the lysis buffer and again cen-
trifuged. 0.4 N HCl/10 % glycerol was added and incu-
bated in 4°C while shaking. The supernatant was
precipitated with 100 % TCA and incubated on ice for
1 h. After centrifugation, histone pellet was washed
with acetone/0.02 N HCl, dried and dissolved in water.
The histones were run on SDS gel, transferred to nylon
membranes and probed overnight at 4°C with rabbit
anti-acetyl Histone 3 lysine14, rabbit anti-acetyl Histone
4 lysine 12, rabbit anti-acetyl Histone H4 lysine 16,
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Histone H4 (Upstate cell signaling solutions) 1:2000
diluted in 1X TBST and 3 % BSA with 0.02 % Sodium
Azide. Appropriate Santa Cruz HRP conjugated second-
ary antibodies (1:3000) were used. Super Signal West
Pico Chemiluminescent Substrate from Pierce was used
as per manufacturer’s protocol for developing the blots.
Indirect Immuno-fluorescence of interphase nuclei
The Colcimid-treated (0.1 μg/ml media for 4–5 hrs) cells
were trypsinized and precipitated at 200 g, and incubated
in 75 mM KCl for 15 min at 37°C and further centrifuged
at 100 g. The pellet was dissolved in 5 ml KCl. 300 μl
was then mounted on the glass slides at 1000 rpm for
8 min. The slides were fixed in 3.7 % formaldehyde,
washed twice with PBS, and treated with PBS containing
0.1 % Triton X-100 and 0.02 % Sodium Azide for 45 min
at RT to permeabilize cells. After a wash with PBS, the
slides were incubated with the primary antibody over-
night at 4°C at 1:200 dilutions with PBT. The slides were
washed with PBS for 10 min and incubated in goat serum
diluted in PBT (1:50) for 30 min at RT. After PBS wash
for 30 min, the slides were counterstained with DAPI
and further visualized using confocal microscopy.
Immunostaining of metaphase chromosomes
We have estimated accumulation of modified histones on
the chromosomal arms by indirect Immuno-fluorescence.
Briefly, metaphase cell spreads on the slides were incubated
for 1 h at 37°C in a humid chamber with serial dilutions with
either primary H3 dimethyl Lys-9 (1:50) or Lys-14 acetyl H3
(1:75) Lys 12 acetyl H4 (1:100) antisera, Lys 16 acetyl H4
(1:100) antisera and washed in KCM (120 mM KCl, 20 mM
NaCl, 10 mM Tris-Cl- pH 8.0, 0.5 M EDTA, 0.1 % Triton).
We had then added Cy3- conjugated, affinity-purified, don-
key anti-rabbit IgG antibody (Jackson Immuno-Research)
diluted 1:100 in KCM, and incubated the mixture for
30 min at room temperature. Chromosomes were further
washed with KCM and fixed in 4 % formaldehyde for
10 min at room temperature. After a wash in sterile water,
chromosomes were counterstained with DAPI, mounted the
cover slips with anti-fade media (Vectashield) and viewed on
a Zeiss Axiophot fluorescence microscope.
Chromatin Immunoprecipitation Assay (ChIP)
Chromatin immunoprecipitation assay was conducted as
described earlier [14] Supplementary protocol). The opti-
mal reaction conditions for PCR were determined for
each primer pair. Parameters were denaturation at 95°C
for 1 min and annealing at 60°C for 1 min, followed by
elongation at 72°C for 1 min. PCR products were ana-
lyzed by 2.5 % agarose/ethidium bromide gel electro-
phoresis. Different primer pairs used for p21WAF1 ChIP
analysis (Supplementary materials).Immunoprecipitation
A375 Cells were washed twice with PBS, scraped and
resuspended in 250 μl of lysis buffer [50 mM Tris (pH-8),
120 mM NaCl, 0.5 % Nonidet P-40, 50 mM NaF, 1 mM
sodium orthovanadate, 100 μg of polymethylsulfonyl fluor-
ide/ml, 20 μg of aprotinin/ml, and 10 μg of leupeptin/ml].
The lysates were incubated on ice for 1 h followed by cen-
trifugation at 12,000 rpm for 10 min to remove the insol-
uble materials. For immunoprecipitations, precleared 0.5
to 1 mg of whole-cell lysates were immunodepleted with
p21antibody for 2 h. To this antibody complex, protein A/
G agarose (Invitrogen, Inc.) beads were added for 1 h and
kept at 4°C in an end-to-end shaker. The beads were
washed thrice with lysis buffer without protease inhibitors.
1× Laemmli buffer was added to the beads, samples were
boiled and loaded on to SDS-PAGE for western blot ana-
lysis using antibodies against STAT-1, 3, 5a.
Real time PCR Analysis
Total cellular RNA from cells was isolated by Trizol and
RNase-Free DNase treatment carried out to remove DNA
contaminants. RNA was purified by RNeasy Mini Kit
(Qiagen, Germany). Three micrograms of RNA was used
for first strand cDNA synthesis using SuperScriptTM (Invi-
trogen, USA). Real-Time PCR (ABI 7900) was performed.
P21 promoter primer sequences for the four different
regions were included in the supplementary information.
Luciferase assay
A375 cells were transfected with wild-type p21-Luc pro-
moter plasmid (1 μg) and CMV-β-galactosidase plasmid
(β-gal) (500 ng); mut-p21-Luc promoter plasmid (STAT
region is mutated) and CMV-βgal plasmid combinations
according to standard transfection protocol. This is
followed by compound treatment [chrysin (40 μM), TSA
(4 μM)]. The luciferase and β-galactosidase values were
determined for each sample separately using Multimode
Varioskan Flash (Thermo scientific) instrument. β-gal
values were used for normalization.Each experiment was
repeated three times and stanadard deviations were derived.
Lipofectamine 2000 (Invitrogen) was used as transfection
reagent.
Transcriptional Run-On Analysis
Nuclei were prepared and run-on transcription assays
were performed as previously described [14] (supplemen-
tary protocol).
Reverse-Transcription PCR
Total RNA was isolated from the cells treated with chrysin
(40 μM) and TSA (4 μM) for 24 h was treated with RNase
free DNAse and column purified. Three microgram of
RNA was taken for first strand synthesis using superscript
reverse transcriptase enzyme (Invitrogen) and PCR was
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atgaaattcaccccctttcc3’ and RP-5’ccctaggctgtgctcacttc3’),
STAT-1 (FP-5’ ccgttttcatgacctcctgt 3’ and RP-5’tgaatatt
ccccgactgagc3’) and GAPDH (FP-5’ acagtcagccgcatc
ttctt 3’ and RP-5’ acaagcttcccgttctcag 3’) was used as
internal control.
Statistical Analysis
Statistical Analysis was performed using the graph pad
software to evaluate the significant difference between
the control and treated samples. All variables were tested
in three independent experiments. The results were
reported as mean± SD. * indicates P <0.05, ** indicates
P< 0.01, *** indicates P< 0.001. P values were obtained
by comparing compound treated cells with untreated
control cells using graph pad software.Additional file
Additional file 1: Supplementary Data
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